Doctoral School of Medicine and Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, 540142 Târgu Mureș, Romania.
Department of Cardiology, Clinical County Hospital Mureș, 540103 Târgu Mureș, Romania.
Biomolecules. 2023 Oct 26;13(11):1578. doi: 10.3390/biom13111578.
Vitamin D emerged as an important prognostic biomarker in heart failure (HF), with currently highly debated therapeutic implications. Several trials on vitamin D supplementation in HF showed improvements in left ventricular (LV) remodeling and function and health-related quality of life (HRQoL), which did not translate into mid- to long-term beneficial effects regarding physical performance and mortality. We addressed total 25-hydroxyvitamin D (25(OH)D), serum albumin, and uric acid (UA) levels, focusing mainly on vitamin D deficiency, as potential markers of LV systolic dysfunction in HF with reduced and mildly reduced ejection fraction (HFrEF, HFmrEF). Seventy patients with LVEF < 50% were comprehensively evaluated using ECG, echocardiography, lung ultrasound (LUS), blood sampling, and the six-minute walk test (6MWT). HRQoL was also assessed using the Minnesota Living with Heart Failure Questionnaire (MLHFQ). Statistically significant positive correlations were found between LVEF, 25(OH)D, serum UA, and albumin, respectively ( = 0.008, = 0.009, and = 0.001). Serum UA (7.4 ± 2.4 vs. 5.7 ± 2.1, = 0.005), NT-proBNP levels (1090.4 (675.2-2664.9) vs. 759.0 (260.3-1474.8), = 0.034), and MLHFQ scores (21.0 (14.0-47.0) vs. 14.5 (4.5-25.5), = 0.012) were significantly higher, whereas 25(OH)D concentrations (17.6 (15.1-28.2) vs. 22.7 (19.5-33.8), = 0.010) were lower in subjects with severely reduced LVEF. Also, 25(OH)D was independently associated with LVEF in univariate and multiple regression analysis, maintaining its significance even after adjusting for confounders such as age, NT-proBNP, the presence of chronic coronary syndrome, hypertension, and anemia. According to our current findings, 25(OH)D is closely associated with LVEF, further supporting the need to establish correct vitamin D supplementation schemes and dietary interventions in HF. The changes in LVEF, 25(OH)D, serum UA, and albumin levels in HFrEF and HFmrEF indicate a similar pathophysiological background.
维生素 D 已成为心力衰竭 (HF) 重要的预后生物标志物,目前具有高度争议的治疗意义。几项关于 HF 中维生素 D 补充的试验表明,左心室 (LV) 重构和功能以及与健康相关的生活质量 (HRQoL) 得到改善,但在体力表现和死亡率方面并未转化为中至长期的有益效果。我们主要关注维生素 D 缺乏症,将总 25-羟维生素 D (25(OH)D)、血清白蛋白和尿酸 (UA) 水平作为 HF 伴射血分数降低和轻度降低 (HFrEF、HFmrEF) 的 LV 收缩功能障碍的潜在标志物。使用心电图、超声心动图、肺部超声 (LUS)、采血和 6 分钟步行测试 (6MWT) 全面评估了 70 名 LVEF<50%的患者。还使用明尼苏达州心力衰竭生活质量问卷 (MLHFQ) 评估 HRQoL。分别发现 LVEF、25(OH)D、血清 UA 和白蛋白之间存在统计学上显著的正相关关系 ( = 0.008、 = 0.009 和 = 0.001)。血清 UA(7.4 ± 2.4 比 5.7 ± 2.1, = 0.005)、NT-proBNP 水平(1090.4(675.2-2664.9)比 759.0(260.3-1474.8), = 0.034)和 MLHFQ 评分(21.0(14.0-47.0)比 14.5(4.5-25.5), = 0.012)明显升高,而 25(OH)D 浓度(17.6(15.1-28.2)比 22.7(19.5-33.8), = 0.010)在严重降低 LVEF 的患者中降低。此外,25(OH)D 在单变量和多变量回归分析中与 LVEF 独立相关,即使在调整年龄、NT-proBNP、慢性冠状动脉综合征、高血压和贫血等混杂因素后,其意义仍然存在。根据我们目前的发现,25(OH)D 与 LVEF 密切相关,进一步支持在 HF 中建立正确的维生素 D 补充方案和饮食干预的必要性。在 HFrEF 和 HFmrEF 中,LVEF、25(OH)D、血清 UA 和白蛋白水平的变化表明存在类似的病理生理背景。